12:00 AM
Apr 30, 2015
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Fcγ receptor IIb (FCGR2B; CD32B)


INDICATION: Chronic lymphocytic leukemia (CLL); mantle cell lymphoma (MCL); leukemia; lymphoma

In vitro and mouse studies suggest inhibiting FCGR2B could help treat leukemias and lymphomas resistant to anti-CD20 therapy. In primary CLL cells, an anti-FCGR2B mAb decreased internalization of rituximab compared with an isotype control. In mouse...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >